Your browser doesn't support javascript.
loading
A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population.
de Abreu, Ariane de Jesus Lopes; Cavalcante, João Roberto; de Araújo Lagos, Letícia Wigg; Caetano, Rosângela; Braga, José Ueleres.
Afiliación
  • de Abreu AJL; Instituto Nacional de Cardiologia, Rio de Janeiro 22240-006, Brazil.
  • Cavalcante JR; Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil.
  • de Araújo Lagos LW; Instituto Nacional de Cardiologia, Rio de Janeiro 22240-006, Brazil.
  • Caetano R; Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil.
  • Braga JU; Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20550-013, Brazil.
Vaccines (Basel) ; 10(5)2022 Apr 30.
Article en En | MEDLINE | ID: mdl-35632466
We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed. The results obtained through the meta-analysis showed a risk of serious adverse events after yellow fever vaccination three times higher for the elderly when compared to the non-elderly population and five times higher for persons > 70 years. In relation to adverse event types, viscerotropic disease associated with the yellow fever vaccine had a risk that was six times higher when compared to the population < 60 years. The evidence found supports that the vaccine indication in individuals > 60 years of age should be based on a careful analysis of individual benefit-risk assessments. The results found suggest a higher risk of events for individuals > 70 years, especially for viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this age group.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies / Systematic_reviews Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies / Systematic_reviews Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza